These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 31104027

  • 1. Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease.
    Skillbäck T, Kornhuber J, Blennow K, Zetterberg H, Lewczuk P, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2019; 69(2):551-559. PubMed ID: 31104027
    [Abstract] [Full Text] [Related]

  • 2. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I, Santana I, Leitão MJ, Vieira D, Duro D, Mroczko B, Kornhuber J, Lewczuk P.
    Alzheimers Res Ther; 2019 Jan 05; 11(1):2. PubMed ID: 30611311
    [Abstract] [Full Text] [Related]

  • 3. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K.
    JAMA Neurol; 2019 Jul 01; 76(7):791-799. PubMed ID: 31009028
    [Abstract] [Full Text] [Related]

  • 4. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH, Cogo-Moreira H, Rabin JS, Black SE, Swardfager W, Alzheimer's Disease Neuroimaging Initiative.
    J Neurosci; 2019 Sep 11; 39(37):7428-7437. PubMed ID: 31350262
    [Abstract] [Full Text] [Related]

  • 5. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP, Ballarini T, Sala A, Cerami C, Presotto L, Santangelo R, Fallanca F, Vanoli EG, Gianolli L, Iannaccone S, Magnani G, Perani D, BIOMARKAPD Project.
    Neuroimage Clin; 2018 Sep 11; 18():167-177. PubMed ID: 29387532
    [Abstract] [Full Text] [Related]

  • 6. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A.
    J Alzheimers Dis; 2015 Sep 11; 45(4):1077-88. PubMed ID: 25649653
    [Abstract] [Full Text] [Related]

  • 7. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M, Barocco F, Michelini G, Immovilli P, Taga A, Morelli N, Ruffini L, Caffarra P.
    Acta Neurol Belg; 2019 Sep 11; 119(3):445-452. PubMed ID: 30847669
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
    Jang H, Park J, Woo S, Kim S, Kim HJ, Na DL, Lockhart SN, Kim Y, Kim KW, Cho SH, Kim SJ, Seong JK, Seo SW, Alzheimer’s Disease Neuroimaging Initiative.
    Neuroimage Clin; 2019 Sep 11; 24():101941. PubMed ID: 31376643
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C, Tucholka A, Monté-Rubio GC, Cacciaglia R, Operto G, Rami L, Gispert JD, Molinuevo JL, Alzheimer's Disease Neuroimaging Initiative.
    Neuroimage Clin; 2018 Sep 11; 19():190-201. PubMed ID: 30023169
    [Abstract] [Full Text] [Related]

  • 12. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
    van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Neurol; 2017 Dec 01; 74(12):1481-1491. PubMed ID: 29049480
    [Abstract] [Full Text] [Related]

  • 13. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
    Marizzoni M, Ferrari C, Macis A, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Pizzini F, Rossini PM, Salvatore M, Schönknecht P, Soricelli A, Del Percio C, Hensch T, Hegerl U, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB, PharmaCog Consortium.
    J Alzheimers Dis; 2019 Dec 01; 69(1):49-58. PubMed ID: 30958351
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF, Reinvang I, Selnes P, Grambaite R, Fladby T, Hessen E.
    Brain Behav; 2017 Sep 01; 7(9):e00776. PubMed ID: 28948074
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.